THWART-TB : Testing Health Workers At Risk to advance our understanding of TB infection

THWART-TB:对处于危险中的卫生工作者进行检测,以增进我们对结核病感染的了解

基本信息

项目摘要

PROJECT SUMMARY Tuberculosis (TB) remains a leading infectious cause of death globally. 1.7 billion people worldwide are estimated to have been infected with TB (LTBI); yet TB infection remains poorly understood. Current LTBI tests cannot distinguish between current infection versus a persistent immune response to a cleared infection and have a low predictive value to identify which people are at risk of developing incident active TB disease. We propose to establish a prospective longitudinal cohort study of health workers (HWs) in Cape Town, South Africa, where our preliminary data reveals HWs have a high annual TB infection risk (34%). This cohort, who will undergo frequent serial evaluation (every 3 months) with a combination of novel assays never previously evaluated together, presents a unique opportunity to evaluate immune responses at the time of initial infection and to characterize the dynamic profile of these immune responses over time in a high-risk population. This interdisciplinary study addresses three knowledge gaps: 1) We will evaluate serial interferon gamma release assay (IGRA) responses to identify early TB infection and characterize the dynamics of IGRA conversion and reversion, which will contribute to understanding of transient versus persistent infection. Furthermore we will elicit HW preferences regarding serial LTBI testing strategies and decision making that will inform the implementation of HW TB screening, which is urgently needed given their occupational TB risk. 2) We will evaluate the temporal dynamics of immune responses to TB by measuring serial RNA biosignatures, C-reactive protein, and Mycobacterium tuberculosis (Mtb)-antibody responses. We will determine whether biosignature results are persistently elevated or wane over time and how these correlate with other measures of immune response. We will be able to comprehensively profile changes in Mtb-antibody responses by not only quantifying IgG levels but by evaluating all isotypes, subclasses and Fc-receptor binding profiles. 3) We will evaluate serial blood samples for detectable Mtb, based on testing of CD34-positive PBMCs and a phage-based assay (Actiphage). Comparing novel Mtb DNA detection approaches could enhance understanding and risk stratification for incident TB in high-risk populations. Our novel data on Mtb immune responses and Mtb quantification in people with LTBI will improve understanding of the correlates of TB immune clearance versus persistence and could help to identify individuals at a higher risk of progression. This study is aligned with the NIAID mission to ‘advance the understanding and diagnosis of re-emerging diseases such as TB’ and to ‘develop international research capacity to respond appropriately to re-emerging disease threats’.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ruvandhi Nathavitharana其他文献

Ruvandhi Nathavitharana的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ruvandhi Nathavitharana', 18)}}的其他基金

Optimizing Diagnostic Strategies for TB Transmission Control in Health-Care Facilities
优化医疗机构中结核病传播控制的诊断策略
  • 批准号:
    10356897
  • 财政年份:
    2018
  • 资助金额:
    $ 118.95万
  • 项目类别:

相似海外基金

Characterizing the SARS-CoV-2 antibody response and associations with patient factors: Serological profiling of participants enrolled in the GENCOV study
描述 SARS-CoV-2 抗体反应及其与患者因素的关联:参与 GENCOV 研究的参与者的血清学分析
  • 批准号:
    495256
  • 财政年份:
    2023
  • 资助金额:
    $ 118.95万
  • 项目类别:
Understanding the human antibody response to a malaria transmission-blocking vaccine
了解人类抗体对疟疾传播阻断疫苗的反应
  • 批准号:
    MR/X009491/1
  • 财政年份:
    2023
  • 资助金额:
    $ 118.95万
  • 项目类别:
    Research Grant
Probing the role of peptidoglycan modification in the antibody response to Staphylococcus aureus
探讨肽聚糖修饰在金黄色葡萄球菌抗体反应中的作用
  • 批准号:
    10549646
  • 财政年份:
    2023
  • 资助金额:
    $ 118.95万
  • 项目类别:
Identification of the antigenic targets of the clonal antibody response to Clostridioides difficile infection
鉴定针对艰难梭菌感染的克隆抗体反应的抗原靶点
  • 批准号:
    10742376
  • 财政年份:
    2023
  • 资助金额:
    $ 118.95万
  • 项目类别:
Genetic, structural and functional profiling of the human antibody response to arenavirus infection
人类抗体对沙粒病毒感染反应的遗传、结构和功能分析
  • 批准号:
    10688292
  • 财政年份:
    2022
  • 资助金额:
    $ 118.95万
  • 项目类别:
Molecular dissection of IgA antibody response by developing monoclonal IgA antibodies from nasal mucosa of mice
通过从小鼠鼻粘膜中开发单克隆 IgA 抗体对 IgA 抗体反应进行分子剖析
  • 批准号:
    22H02875
  • 财政年份:
    2022
  • 资助金额:
    $ 118.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mapping the antibody response to Trypanosoma brucei variant surface glycoprotein
绘制布氏锥虫变异表面糖蛋白的抗体反应
  • 批准号:
    10634694
  • 财政年份:
    2022
  • 资助金额:
    $ 118.95万
  • 项目类别:
Genetic, structural and functional profiling of the human antibody response to arenavirus infection
人类抗体对沙粒病毒感染反应的遗传、结构和功能分析
  • 批准号:
    10514498
  • 财政年份:
    2022
  • 资助金额:
    $ 118.95万
  • 项目类别:
Factors related to antibody response of COVID-19 vaccines: with focusing on metabolomics
与 COVID-19 疫苗抗体反应相关的因素:重点关注代谢组学
  • 批准号:
    22H03334
  • 财政年份:
    2022
  • 资助金额:
    $ 118.95万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mapping the antibody response to Trypanosoma brucei variant surface glycoprotein
绘制布氏锥虫变异表面糖蛋白的抗体反应
  • 批准号:
    10527979
  • 财政年份:
    2022
  • 资助金额:
    $ 118.95万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了